• +1-646-491-9876
    • +91-20-67278686

    Search

    Stroke Pipeline Review H1 2017

    Stroke Pipeline Review H1 2017

    • Report Code ID: RW0001799293
    • Category Pharmaceuticals
    • No. of Pages 461
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Stroke - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H1 2017, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

    Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 22, 15, 1, 87 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 3 molecules, respectively.

    Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 6
    Stroke - Overview 7
    Stroke - Therapeutics Development 8
    Stroke - Therapeutics Assessment 30
    Stroke - Companies Involved in Therapeutics Development 46
    Stroke - Drug Profiles 88
    Stroke - Dormant Projects 418
    Stroke - Discontinued Products 427
    Stroke - Product Development Milestones 430
    Appendix 442

    List of Tables

    Number of Products under Development for Stroke, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Stroke - Pipeline by AB Science SA, H1 2017
    Stroke - Pipeline by Acticor Biotech SAS, H1 2017
    Stroke - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
    Stroke - Pipeline by Addex Therapeutics Ltd, H1 2017
    Stroke - Pipeline by Affibody AB, H1 2017
    Stroke - Pipeline by Anavex Life Sciences Corp, H1 2017
    Stroke - Pipeline by Angion Biomedica Corp, H1 2017
    Stroke - Pipeline by Antoxis Ltd, H1 2017
    Stroke - Pipeline by ArmaGen Inc, H1 2017
    Stroke - Pipeline by Artielle ImmunoTherapeutics Inc, H1 2017
    Stroke - Pipeline by Asterias Biotherapeutics Inc, H1 2017
    Stroke - Pipeline by Athersys Inc, H1 2017
    Stroke - Pipeline by Bayer AG, H1 2017
    Stroke - Pipeline by Bioasis Technologies Inc, H1 2017
    Stroke - Pipeline by Biogen Inc, H1 2017
    Stroke - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Stroke - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Stroke - Pipeline by Cardax Inc, H1 2017
    Stroke - Pipeline by Cellular Biomedicine Group Inc, H1 2017
    Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017
    Stroke - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
    Stroke - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017
    Stroke - Pipeline by D-Pharm Ltd, H1 2017
    Stroke - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Stroke - Pipeline by DiaMedica Therapeutics Inc, H1 2017
    Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
    Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Stroke - Pipeline by Fina Biotech SL, H1 2017
    Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
    Stroke - Pipeline by Glialogix Inc, H1 2017
    Stroke - Pipeline by Glucox Biotech AB, H1 2017
    Stroke - Pipeline by Green Cross Corp, H1 2017
    Stroke - Pipeline by Huons Co Ltd, H1 2017
    Stroke - Pipeline by Immunwork Inc, H1 2017
    Stroke - Pipeline by International Stem Cell Corp, H1 2017
    Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
    Stroke - Pipeline by JN-International Medical Corp, H1 2017
    Stroke - Pipeline by JT Pharmaceuticals Inc, H1 2017
    Stroke - Pipeline by Les Laboratoires Servier SAS, H1 2017
    Stroke - Pipeline by Living Cell Technologies Ltd, H1 2017
    Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H1 2017
    Stroke - Pipeline by M et P Pharma AG, H1 2017
    Stroke - Pipeline by Magnus Life Ltd, H1 2017
    Stroke - Pipeline by Mapreg SAS, H1 2017
    Stroke - Pipeline by Medestea Research & Production SpA, H1 2017
    Stroke - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
    Stroke - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Stroke - Pipeline by Neuralstem Inc, H1 2017
    Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
    Stroke - Pipeline by Neurofx Inc, H1 2017
    Stroke - Pipeline by Neuronax SAS, H1 2017
    Stroke - Pipeline by NeuroSearch A/S, H1 2017
    Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
    Stroke - Pipeline by New World Laboratories Inc, H1 2017
    Stroke - Pipeline by NoNO Inc, H1 2017
    Stroke - Pipeline by Novartis AG, H1 2017
    Stroke - Pipeline by NuvOx Pharma LLC, H1 2017
    Stroke - Pipeline by Omeros Corp, H1 2017
    Stroke - Pipeline by Omniox Inc, H1 2017
    Stroke - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
    Stroke - Pipeline by Pharmaxis Ltd, H1 2017
    Stroke - Pipeline by Pharmicell Co Ltd, H1 2017
    Stroke - Pipeline by Phoenix Biotechnology Inc, H1 2017
    Stroke - Pipeline by PhytoHealth Corp, H1 2017
    Stroke - Pipeline by Pluristem Therapeutics Inc, H1 2017
    Stroke - Pipeline by QR Pharma Inc, H1 2017
    Stroke - Pipeline by ReCyte Therapeutics Inc, H1 2017
    Stroke - Pipeline by Remedy Pharmaceuticals Inc, H1 2017
    Stroke - Pipeline by ReNeuron Group Plc, H1 2017
    Stroke - Pipeline by Rubicon Biotechnology Inc, H1 2017
    Stroke - Pipeline by SanBio Inc, H1 2017
    Stroke - Pipeline by Saneron CCEL Therapeutics Inc, H1 2017
    Stroke - Pipeline by Savara Inc, H1 2017
    Stroke - Pipeline by Shin Poong PharmCo Ltd, H1 2017
    Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2017
    Stroke - Pipeline by Stemedica Cell Technologies Inc, H1 2017
    Stroke - Pipeline by SynZyme Technologies LLC, H1 2017
    Stroke - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
    Stroke - Pipeline by TikoMed AB, H1 2017
    Stroke - Pipeline by Verseon Corp, H1 2017
    Stroke - Pipeline by Vicore Pharma AB, H1 2017
    Stroke - Pipeline by Virogenomics BioDevelopment Inc, H1 2017
    Stroke - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
    Stroke - Pipeline by Zocere Inc, H1 2017
    Stroke - Dormant Projects, H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Stroke - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Stroke - Discontinued Products, H1 2017
    Stroke - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Stroke - Discontinued Products, H1 2017 (Contd..2) , H1 2017

    List of Figures

    Number of Products under Development for Stroke, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AB Science SA
    Acticor Biotech SAS
    ActiveSite Pharmaceuticals Inc
    Addex Therapeutics Ltd
    Affibody AB
    Anavex Life Sciences Corp
    Angion Biomedica Corp
    Antoxis Ltd
    ArmaGen Inc
    Artielle ImmunoTherapeutics Inc
    Asterias Biotherapeutics Inc
    Athersys Inc
    Bayer AG
    Bioasis Technologies Inc
    Biogen Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Cardax Inc
    Cellular Biomedicine Group Inc
    CHA Bio & Diostech Co Ltd
    ContraVir Pharmaceuticals Inc
    CSPC Pharmaceutical Group Limited
    D-Pharm Ltd
    Daiichi Sankyo Company Ltd
    DiaMedica Therapeutics Inc
    Diffusion Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    Fina Biotech SL
    Genervon Biopharmaceuticals LLC
    Glialogix Inc
    Glucox Biotech AB
    Green Cross Corp
    Huons Co Ltd
    Immunwork Inc
    International Stem Cell Corp
    Jeil Pharmaceutical Co Ltd
    JN-International Medical Corp
    JT Pharmaceuticals Inc
    Les Laboratoires Servier SAS
    Living Cell Technologies Ltd
    Lumosa Therapeutics Co Ltd
    M et P Pharma AG
    Magnus Life Ltd
    Mapreg SAS
    Medestea Research & Production SpA
    Mitochon Pharmaceuticals Inc
    Mitsubishi Tanabe Pharma Corp
    Neuralstem Inc
    Neuren Pharmaceuticals Ltd
    Neurofx Inc
    Neuronax SAS
    NeuroSearch A/S
    NeuroVive Pharmaceutical AB
    New World Laboratories Inc
    NoNO Inc
    Novartis AG
    NuvOx Pharma LLC
    Omeros Corp
    Omniox Inc
    Panacea Pharmaceuticals Inc
    Pharmaxis Ltd
    Pharmicell Co Ltd
    Phoenix Biotechnology Inc
    PhytoHealth Corp
    Pluristem Therapeutics Inc
    QR Pharma Inc
    ReCyte Therapeutics Inc
    Remedy Pharmaceuticals Inc
    ReNeuron Group Plc
    Rubicon Biotechnology Inc
    SanBio Inc
    Saneron CCEL Therapeutics Inc
    Savara Inc
    Shin Poong PharmCo Ltd
    Simcere Pharmaceutical Group
    Stemedica Cell Technologies Inc
    SynZyme Technologies LLC
    Tasly Pharmaceutical Group Co Ltd
    TikoMed AB
    Verseon Corp
    Vicore Pharma AB
    Virogenomics BioDevelopment Inc
    WhanIn Pharmaceutical Co Ltd
    Zocere Inc

    Request for Sample

    Report Url http://www.reportsweb.com//stroke-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//stroke-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//stroke-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments